The global pharma contract sales market is expected to grow at a CAGR of 7.9% in the first half of the forecast period. In 2019, the contract detailing segment held 76% of the global pharma contract sales market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 244-page report you will receive 77 tables and 62 figures– all unavailable elsewhere.
The 244-page report provides clear detailed insight into the global pharma contract sales market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Pharma Contract Sales Market forecasts from 2020-2030
• Along with revenue prediction for the overall world market for pharma contract sales market, our investigation shows forecasts to 2030 for the following submarket by leading services:
• Contract detailing (personal promotion/field sales)
• Contract non-personal promotion, with further sub-forecasting for teledetailing, eDetailing and others
• Medical education services
• Sample management services
• This report also breaks down the revenue forecast for pharma contract sales market by therapeutic segments:
• Cardiovascular disease
• Metabolic disorders
• Oncology
• Other
• This report provides individual revenue forecasts to 2030 for these regional and national markets:
• US
• Japan
• EU5: Germany, UK, France, Italy and Spain
• BRIC: China, India, Brazil and Russia
The US, Japan, EU5 and BRIC markets are further segmented by therapeutic segments and leading services
• Our study discusses the SWOT and STEP factors of the global pharma contract sales market
• Our study also discusses factors that will drive and restrain the global pharma contract sales market
• Our study discusses issues affecting the pharma contract sales industry and market:
• Outsourced and in-house sales reps – trends and emerging sales models, including multiple channels (multichannel marketing to medical professionals)
• Services CSOs offer and benefits to drug companies outsourcing medical sales
• Maturing brands and product launches, including flexibility in field sales teams
• Legislation and new market access requirements for pharma sales representatives
• Changes to online marketing and potential for IT technologies Risk-sharing agreements
• Key account management (KAM) and medical science liaison (MSL)
• This report discusses the leading companies in pharma contract sales:
• Apodi
• CMIC
• inVentiv Health (Syneos Health)
• IQVIA
• Marvecs
• OnCall, LLC
• Publicis Healthcare Communications Group
• Sofip
• Star Healthcare
• UDG Healthcare
• Key questions answered by this report:
• How much is the global pharma contract sales market currently worth, and how much will it be worth during the period 2020-2030?
• What are the leading therapeutic submarkets from 2020-2030?
• What are the leading services submarkets from 2020-2030?
• What are the leading national markets and the leading emerging markets from 2020-2030? What are the regulatory landscapes in these nations?
• What are the main trends that will shape this market over the next ten years, and the main drivers and restraints?
• Who are the leading CSOs in this market?
Visiongain’s study is intended for anyone requiring commercial analyses for the global pharma contract sales market. You find data, trends and predictions.
Buy our report today Global Pharma Contract Sales Market Forecast: Contract Detailing, Contract Non-Personal Promotion, Medical Education Services, Sample Management Services, Teledetailing Services, Edetailing Services, Cardiovascular Disease, Metabolic Disorders, Oncology.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Pharma Contract Sales Overview
1.2 Why You Should Read This Report
1.3 How this Report Delivers
1.4 Main Questions Answered by this Report
1.5 Who is this Report for?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Reports
1.9 About Visiongain
2. Introduction to Pharma Contract Sales Market
2.1 Defining the Market
2.2 What is a CSO?
2.3 What Services do CSOs Provide?
2.4 Marketing Channels Employed by Pharma Companies in 2019
2.5 Growing Trend of Outsourcing in the Overall Pharma Industry
2.6 Detailing: Becoming Less Relevant or is it as Important as Ever?
2.6.1 Declining Access to Doctors: Trend Continues in 2019
2.7 Large Cuts in Sales Force in Various Companies
2.8 Companies Cannot Rely Solely Upon Detailing
2.8.1 Trends Driving the Need for New Sales Models
3. Global Pharma Contract Sales Market 2020-2030
3.1 The Market in 2019
3.2 Global Pharma Contract Sales Market 2018-2024
3.2.1 Growth in the Market in Recent Years
3.3 The Factors that Will Drive Growth in this Market: Advantages of Outsourcing Pharma Sales
3.3.1 Cost and Flexibility
3.3.2 New Technologies and Sales Models
3.3.3 Emerging Markets and Mature Brands
3.3.4 Biosimilars
3.3.5 Account Management, Medical Education and Patient Support Services
3.3.6 Market Access Complexities Provide its Own Opportunities for CSOs
3.3.7 New Drug Launches
3.3.8 Summary
3.4 The Factors that Will Restrain Growth in this Market: Disadvantages of Outsourcing Pharma Sales
3.5 Leading Therapeutic Submarkets for Pharma Contract Sales, Forecast 2020-2030
3.6 The Rise in Pharma Contract Sales
3.7 How Will the Therapeutic Composition of the Market Change Between 2019 and 2030?
3.8 Contract Sales for Cardiovascular Drugs
3.8.1 Current Status
3.8.2 Recent Cardiovascular Drug Patent Expiries and FDA Approvals
3.8.3 Cardiovascular and Cerebrovascular Conditions are the World’s Most Fatal Diseases
3.8.4 Contract Sales for Cardiovascular Drugs: Submarket Forecast 2020-2030
3.9 Contract Sales for Metabolic Disorder Drugs
3.9.1 Current Status
3.9.2 430 Million People Expected to be Diagnosed with Diabetes by 2030
3.9.3 Contract Sales for Metabolic Disorders: Submarket Forecast 2020-2030
3.10 Contract Sales for Oncology Drugs
3.10.1 Current Status
3.10.2 Patent Expiries and Recent Approvals
3.10.3 Contract Sales for Oncology Drugs Forecast 2020-2029
4. Leading Service Sectors of the Pharma Contract Sales Market 2020-2030
4.1 The Leading Services
4.1.1 Leading Service Sectors of the Market, Forecast 2020-2030
4.1.2 How Will the Service Composition over the Market Change over the Next Ten Years?
4.2 Contract Detailing Submarket
4.2.1 Are we in the Midst of a Turnaround in Sales Rep Numbers in the Overall Pharma Industry?
4.2.2 What are the Trends in Sales Reps Employed by CSOs?
4.2.3 Detailing Services Offered by CSOs
4.2.4 CSOs will be Impacted by Declining Physician Access as Much as In-House Reps
4.2.5 Contract Detailing Submarket Forecast 2020-2030
4.2.6 Drivers and Restraints for this Dominant Service Submarket
4.3 Contract Non-Personal Promotion Submarket
4.3.1 The Benefits for both Pharma Companies and Doctors
4.3.2 Contract Non-Personal Promotion Submarket Forecast 2020-2030
4.3.3 Drivers and Restraints for Contract Non-Personal Promotion: Multichannel Marketing in the 21st Century
4.3.4 Further Sub-Sectors Within the Contract Non-Personal Promotion Submarket: Tele-detailing and E-Detailing
4.3.4.1 Contract Tele-detailing Submarket: Current Status
4.3.4.2 Contract Tele-detailing Submarket Forecast 2020-2030
4.3.4.3 Drivers and Restraints for Outsourced Tele-detailing
4.3.4.4 Contract e-Detailing Current Status
4.3.4.5 Contract eDetailing Submarket Forecast 2020-2030
4.3.4.6 Drivers and Restraints for Outsourced eDetailing
4.4 Medical Education Services Submarket Current Status
4.4.1 Medical Education Services Submarket Forecast 2020-2030
4.4.2 Medical Education Services Drivers and Restraints
4.5 Sample Management Services Submarket: Current Status
4.5.1 Sample Management Services Submarket Forecast 2020-2030
4.5.2 Drivers and Restraints for the Sample Management Services Submarket
4.5.3 J. Knipper and Company Inc.: A US Leader in Sample Management Services
4.5.3.1 Company Acquires Sample Management Divisions from Leading CSOs 2010-2014
4.5.3.2 Construction Underway for New State of the Art Distribution Centre
4.5.3.3 New Multi-Million Dollar Contact Centre Opened
4.5.3.4 New Technologies to Drive Growth over the Next Ten Years
5. Leading National Markets for Pharma Contract Sales: Regulatory and Commercial Outlook 2020-2030
5.1 Current Leading National Markets
5.2 Leading Regional Markets Forecast 2020-2030
5.3 How will the Regional Composition of the Market Change between now and 2030?
5.4 Pharma Sales Regulatory Developments
5.4.1 Physician Payment Legislation in the US, Europe and Japan
5.4.1.1 The Physician Payment Sunshine Act (PPSA)
5.4.1.2 Proposed Bill to Close a Large Loophole in the PPSA, comes into Effect in 2018
5.4.1.3 Physician Payments in France: Increased Scrutiny
5.4.2 Domestic and International Concerns over Bribery: Recent Legislation in the US and UK
5.4.2.1 Promotional Products in the EU: New Rules
5.4.3 New Market Access Requirements in EU5 Countries
5.4.3.1 AMNOG: Stricter Pricing for Drugs in Germany
5.4.3.2 AMNOG: Has Reduced Prices of Top Sellers by 23%
5.4.3.3 Healthcare Reform in France: Pricing and Reimbursements have been set to Change for a While, is 2020 the Year It Finally Happens?
5.4.3.4 PCTs Replaced by CCGs in the UK
5.4.3.5 Pricing in the UK: Contentious Issue
5.4.4 Overtime for Sales Reps in the US: Rule Clarifications
5.5 US Pharma Contract Sales Market
5.5.1 US Pharma Contract Sales Market Has Grown Rapidly
5.5.2 Pharma Sales Regulation in the US
5.5.3 US Pharma Contract Sales Market Forecast 2020-2030
5.6 EU5 Pharma Contract Sales Market
5.6.1 Regulating Pharma Sales in the EU
5.6.2 Overall EU5 Pharma Contract Sales Market Forecast 2020-2030
5.6.3 UK Pharma Contract Sales Market Forecast 2020-2030
5.6.4 German Pharma Contract Sales Market Forecast 2020-2030
5.6.5 French Pharma Contract Sales Market Forecast 2020-2030
5.6.6 Italian Pharma Contract Sales Market Forecast 2020-2030
5.6.7 Spanish Pharma Contract Sales Market Forecast 2020-2030
5.7 Japanese Pharma Contract Sales Market
5.7.1 Regulation
5.7.2 Current Market Landscape
5.7.3 Japanese Pharma Contract Sales Market Forecast 2020-2030
6. Leading Emerging Markets for Pharma Contract Sales: Regulatory and Commercial Outlook 2020-2030
6.1 Pharma Contract Sales in Leading Emerging Markets in 2019
6.2 BRIC Pharma Contract Sales Markets Forecast 2020-2030
6.3 Chinese Pharma Contract Sales Market
6.3.1 Current Pharma Contract Sales Landscape in China
6.3.2 Rising In-House and Outsourced Sales Numbers
6.3.3 Concerns over Bribery
6.3.4 Chinese Pharma Contract Sales Market Forecast 2020-2030
6.4 Indian Pharma Contract Sales Market
6.4.1 Current Pharma Contract Landscape in India
6.4.2 Government and Regulatory Guidelines for Interactions between Healthcare Professionals and Pharma Companies
6.4.3 Indian Pharma Contract Sales Market Forecast 2020-2030
6.5 Brazilian Pharma Contract Sales Market
6.5.1 Current Pharma Contract Sales Landscape in Brazil
6.5.2 State Payment Rules and Online Marketing Rules for Prescription Drugs
6.5.3 Brazilian Pharma Contract Sales Market Forecast 2020-2030
6.6 Russian Pharma Contract Sales Market
6.6.1 Current Pharma Contract Sales Landscape in Russia
6.6.2 New State Procurement Rules for Drugs Introduced in 2013
6.6.3 Tougher Rules on Interactions between Doctors and Sales Reps in Russia
6.6.4 Russian Pharma Contract Sales Market Forecast 2020-2030
7. Pharma Contract Sales: Industry and Market Trends 2020-2030
7.1 Strengths and Weaknesses for the Global Pharma Contract Sales Market 2020-2030
7.2 Opportunities and Threats for the Global Pharma Contract Sales Market 2020-2030
7.3 Pharma Contract Sales Market: STEP Analysis 2020-2030
7.3.1 Social Factors Affecting Pharma Contract Sales to 2030
7.3.1.1 The Role of Ethics in Pharma Sales
7.4 Technological Developments to Improve Sales Strategies
7.4.1 Advantages of Using Tablets and Smartphones for Detailing
7.4.1.1 CSOs Need to Maximise on the Benefits of New Technologies
7.4.2 Closed Loop Marketing (CLM)
7.4.3 Customer Relationship Management (CRM)
7.4.4 The Advantages of Cloud Computing in Pharma Contract Sales
7.4.5 Does Big Data Have a Role in Pharma Sales?
7.4.6 Social Media in Relation to Pharma Sales
7.4.6.1 FDA Releases Long-Awaited Guidance on the use of Social Media
7.4.6.2 Pharma Industry is not Using Social Media to its Full Potential, but it offers many Benefits
7.5 Economic Pressures are Limiting Healthcare and Marketing Budgets
7.6 Political Issues: Stricter Regulations for Pharma Sales around the World
7.7 Trends in Pharma Contract Sales 2020-2030
7.7.1 Cuts to In-House Sales Staff Will Continue 2020-2030
7.7.2 There will be in an Increase in Strategic Partnering in Order to Provide Long-Term Revenue Growth
7.7.3 Leading CSOs have consolidated, and will continue to Consolidate, in Order to Increase Market Penetration
7.7.4 CSOs and Pharma Clients Alike Need to Stay Vigilant about the Risks of Outsourcing Pharma Sales
7.8 Drug Development Trends Affecting Pharma Sales 2020-2030
7.8.1 How will Orphan Drug Diseases Influence Pharma Contract Sales?
7.8.2 Promotion for Biosimilar Drugs over the Next Ten Years
7.8.3 There will be Greater Demand for Specialty Medicines
7.8.4 Emerging National Markets are Becoming Increasingly Important
7.9 Sales Models Need to Evolve
7.9.1 Why are Sales Reps Struggling for Access?
7.9.1.1 One way to Fight Against Reduced Access is to Target the System as a Whole
7.9.1.2 Multichannel Marketing to Overcome Problems of Access
7.9.2 Key Account Management (KAM)
7.9.3 Silos in Sales and Marketing
7.9.4 The Use of KOLs in Pharma Sales
7.10 Market Access
7.10.1 Emerging Stakeholders in Pharma Sales
7.10.2 The Rise of ACOs
7.10.2.1 20% of US Hospitals were Part of an ACO in 2014
7.10.3 Market Access in the EU Over the Next Ten Years
7.10.4 CSOs and Market Access Consulting
7.11 Summary: Main Trends Shaping Pharma Contract Sales 2020-2030
8. Leading Contract Sales Organisations (CSOs)
8.1 Current Industry Landscape
8.2 IQVIA HOLDINGS INC. (Quintiles & IMS)
8.2.1 World Market Leader for Contract Sales and Market Access
8.2.2 New Services and Strategic Partnerships
8.2.3 IQVIA Integrated Health Services Segment Performance 2010-2015
8.2.4 IQVIA Performance 2014-2018
8.2.5 Outlook for QuintilesIMS Contract Sales to 2030
8.2.6 QuintilesIMS Financial Performance Quarterly Review 2018
8.2.7 IQIVA CSO Work Force Review, 2019
8.2.8 IQIVA CSO Current Trends 2020-2030
8.3 UDG Healthcare
8.3.1 Global Service Provider with Various Business Units
8.3.2 Geographic and Service Growth Through Acquisitions
8.3.3 Joint Venture with CMIC
8.3.4 UDG Healthcare Financial Performance 2014-2018 and Beyond
8.3.5 Employees of UDG Healthcare
8.3.6 Current trends UDG Healthcare
8.4 inVentiv Health (Syneos Health)
8.4.1 Combined CRO and CCO
8.4.2 Global Structure
8.4.3 inVentiv Health Presence in US, EU and Asia
8.4.4 Possible $500m IPO in the Near Future
8.4.5 inVentiv Health Contract Sales Outlook to 2030
8.4.6 inVentiv Health Contract Sales Human resource
8.5 Publicis Healthcare Communications Group
8.5.1 PHCG Purchases PDI Commercial Services Business
8.5.1.1 PDI Prior to Acquisition: Broad Service Portfolio, Resources which PHCG now Acquires
8.5.1.2 PDI Past Financial Performance
8.5.2 Publicis Touchpoint Solutions
8.5.2.1 New Services in Recent Years, and Tardis Medical to be Aligned with the Company
8.5.3 Publicis CSO Workforce
8.5.4 Publicis Current Trends 2020-2030
8.6 OnCall, LLC
8.6.1 Range of Services
8.6.2 Contracts with Promius Pharma
8.6.3 OneCall CSO Workforce
8.6.4 OneCall Current Trend 2020-2030
8.7 Marvecs
8.7.1 A Local Leader in Germany
8.7.2 New Services Added in Recent Years: Sales 3.0
8.8 Sofip
8.9 CMIC
8.9.1 CSO Business in Japan Since 2000
8.9.2 CSO Business Workforce
8.10 Leading Players in China are not Just CSOs
8.11 APODI
8.11.1 Financial of Apodi
8.11.2 Apodi CSO Workforce
8.12 Star Healthcare (a Uniphar group)
8.12.1 Financials
8.12.2 CSO workforce
9. Conclusions
9.1 The Global Pharma Contract Sales Market in 2019
9.1.1 Which Sectors Generated the Most Revenues in 2019?
9.1.2 Spending on Contract Sales is Highest in the US and EU
9.2 Outlook for the Pharma Contract Sales Market 2020-2030
9.2.1 Growth Trends for the Leading Submarkets 2020-2030
9.2.1.1 Therapeutic Sector Growth 2020-2030
9.3 Commercial Drivers for Pharma Contract Sales
Associated Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain report evaluation form
List of Table
Table 2.1 Recent Big Pharma Sales Force Cuts, Based Upon Reports and Predictions
Table 3.1 Global Pharma Contract Sales Market: Revenues ($bn), AGR (%),
CAGR (%), 2019-2030
Table 3.2 Pharma Contract Sales Market Segmented by Therapeutic Area:
Revenue ($bn), AGR (%), CAGR (%), 2020-2030
Table 3.3 Leading Therapeutic Submarket Shares (%), 2020-2030
Table 3.4 Selected Cardiovascular Drugs Going Off-Patent
2018-2025
Table 3.5 Cardiovascular Drugs Approved by the FDA in 2015-2019
Table 3.6 Projected Global Deaths from Ischaemic Heart Disease and Stroke (millions), % of Total Deaths, Deaths Per 100,000 Population, 2015 and 2030
Table 3.7 Cardiovascular Disease Submarket Forecast: Revenue ($bn),
AGR (%), CAGR (%), 2020-2030
Table 3.8 Selected Metabolic Disorder Drugs Going Off-Patent 2016-2022
Table 3.9 Diabetes Prevalence in Leading National Markets,
2019
Table 3.10 Metabolic Disorders Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2030
Table 3.11 Selected Recent and Future Oncology Patent Expiries, 2020
Table 3.12 Oncology Drugs Approved by the FDA in 2015
Table 3.13 Oncology Drugs Approved by the FDA
Table 3.14 Oncology Drugs Approved by the FDA in 2018-2020
Table 3.15 Oncology Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2030
Table 3.16 Selected Drugs Which Have Faced Market Access Challenges from NICE, 2013-2015
Table 4.1 Pharma Contract Sales Market Segmented by Service Sectors: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2030
Table 4.2 Contract Detailing Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2030
Table 4.3 Contract Non-Personal Promotion Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2030
Table 4.3. Further Sub-Sectors Within the Contract Non-Personal Promotion Submarket, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2030
Table 4.4 Contract Tele-detailing Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2030
Table 4.5 Contract eDetailing Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2030
Table 4.6 Medical Education Services Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2030
Table 4.7 Sample Management Services Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2030
Table 5.1 Leading Regional Pharma Contract Sales Markets: Forecast Revenue ($bn), AGR (%), CAGR (%), Market Shares (%), 2020-2030
Table 5.2 US Contract Sales Market: Revenue ($bn), CAGR (%),1995 and 2018
Table 5.3 US Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share, 2020-2030
Table 5.4 US Contract Sales Market Forecast: Revenue for Service Area ($bn), AGR (%), CAGR (%), Market Share, 2020-2030
Table 5.5 US Contract Sales Market Forecast: Revenue for Therapeutic Sectors ($bn), AGR (%), CAGR (%), Market Share, 2020-2030
Table 5.6 EU5 Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share, 2020-2030
Table 5.7 EU5 Contract Sales Market Forecast: Revenue for Therapeutic Area ($bn), AGR (%), CAGR (%), Market Share, 2020-2030
Table 5.8 EU5 Contract Sales Market Forecast: Revenue for Service Sectors ($bn), AGR (%), CAGR (%), Market Share, 2020-2030
Table 5.9 UK Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share, 2020-2030
Table 5.10 German Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2018-2024
Table 5.11 French Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2020-2030
Table 5.12 Italian Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2020-2030
Table 5.13 Spanish Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2020-2030
Table 5.14 Japanese Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2020-2030
Table 5.15 Japan Contract Sales Market Forecast: Revenue for Therapeutic Area ($bn), AGR (%), CAGR (%), Market Share, 2020-2030
Table 5.16 Japan Contract Sales Market Forecast: Revenue for Service Sectors ($bn), AGR (%), CAGR (%), Market Share, 2020-2030
Table 6.1 BRIC Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2020-2030
Table 6.2 BRIC Contract Sales Market Forecast: Revenue for Therapeutic Area ($bn), AGR (%), CAGR (%), Market Share, 2020-2030
Table 6.3 BRIC Contract Sales Market Forecast: Revenue for Service Sectors ($bn), AGR (%), CAGR (%), Market Share, 2020-2030
Table 6.4 Chinese Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2020-2030
Table 6.5 Indian Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2020-2030
Table 6.6 Brazilian Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2020-2030
Table 6.7 Russian Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2020-2030
Table 7.1 Pharma Contract Sales Market: Strengths and Weaknesses 2020-2030
Table 7.2 Pharma Contract Sales Market: Opportunities and Threats 2020-2030
Table 7.3 Top 10 US Patent Expiries, 2015
Table 7.4 Notable US Patent Expiries, 2014
Table 7.5 Selected CRM Providers for Pharma Sales, 2016
Table 7.6 Orphan Drug Definitions in Leading Regions
Table 7.7 Orphan Drug Pipeline by Disease Area, 2013
Table 8.1 IQVIA Emerging Market Entries, 2010-2019
Table 8.2 IQVIA: Revenues ($bn), AGR (%), CAGR (%), 2014-2018
Table 8.3 The CSO Work Force in IQIVA
Table 8.4 UDG Healthcare Group Profile, Business Units and Areas of Expertise, 2019
Table 8.5 UDG Healthcare: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
Table 8.6 UDG Healthcare divisions, profit and employees
Table 8.7 The CSO Work Force in UDG Healthcare
Table 8.8 inVentiv Health Commercial Division Subsidiaries, 2019
Table 8.9 The CSO Work Force in Syneos Health
Table 8.10 PDI: Commercial Services Revenues ($bn), AGR (%), CAGR (%), 2010-2014
Table 8.11 The CSO Work Force in PHC Group
Table 8.12 The CSO Work Force in OnCall
Table 8.13 The CSO Work Force in CMIC
Table 8.14 The CSO Work Force in Apodi
Table 8.15 The CSO Work Force in Uniphar
Table 9.1 Pharma Contract Sales Market: Revenues ($bn), CAGR (%) and Market Shares (%) by Sector, 2019, 2025, 2030
Table 9.2 Pharma Contract Sales Market: Revenues ($bn), CAGR (%) and Market Shares (%) by Therapeutic Area, 2019, 2025, 2030
List of Figure
Figure 2.1 The Services Offered by CSOs that Comprise the Pharma Contract Sales Market, 2020
Figure 2.2 Outsourcing Processes in the Pharma Industry, 2019
Figure 2.3 Trends Driving the Need for New Sales Models 2020-2030
Figure 3.1 Global Pharma Contract Sales Market: Revenues ($bn), 2019-2030
Figure 3.2 FDA New Drug Approvals, 2015-2019
Figure 3.3 Pharma Contract Sales: Market Growth Drivers, 2020-2030
Figure 3.4 Pharma Contract Sales Market: Restraints, 2020-2030
Figure 3.5 Pharma Contract Sales Market Segmented by Therapeutic Area (Line Graph): Revenue ($bn), 2020-2030
Figure 3.6 Pharma Contract Sales Market Segmented by Therapeutic Area Market Share (in %), 2020-2030
Figure 3.7 Pharma Contract Sales Market Segmented by Therapeutic Area: Market Shares (%), 2019
Figure 3.8 Pharma Contract Sales Market Segmented by Therapeutic Area: Market Shares (%), 2025
Figure 3.9 Pharma Contract Sales Market Segmented by Therapeutic Area: Market Shares (%), 2030
Figure 3.10 Projected Global Deaths from Ischaemic Heart Disease and Stroke (millions), 2015 and 2030
Figure 3.11 Cardiovascular Disease Submarket Forecast: Revenue ($bn), 2020-2030
Figure 3.12 Diabetes Prevalence in Leading National Markets, 2019
Figure 3.13 Metabolic Disorders Submarket Forecast: Revenue ($bn), 2020-2030
Figure 3.14 Oncology Submarket Forecast: Revenue ($bn), 2020-2030
Figure 4.1 Pharma Contract Sales Market Segmented by Service Sectors: Revenue ($bn), 2020-2030
Figure 4.2 Pharma Contract Sales Market Segmented by Service Sectors: Market Share (%), 2019
Figure 4.3 Pharma Contract Sales Market Segmented by Service Sectors: Market Share (%), 2025
Figure 4.4 Pharma Contract Sales Market Segmented by Service Sectors: Market Share (%), 2030
Figure 4.5 Contract Detailing Submarket Forecast: Revenue ($bn), 2020-2030
Figure 4.6 Contract Detailing Submarket: Drivers and Restraints, 2018-2029
Figure 4.7 Contract Non-Personal Promotion Submarket Forecast: Revenue ($bn), 2020-2030
Figure 4.8 Contract Non-Personal Promotion Submarket Drivers and Restraints, 2020-2030
Figure 4.9 Further Sub-Sectors Within the Contract Non-Personal Promotion Submarket: Forecast: Revenues ($bn), 2020-2030
Figure 4.10 Further Sub-Sectors Within the Contract Non-Personal Promotion Submarket: Market Shares (%), 2019
Figure 4.11 Further Sub-Sectors Within the Contract Non-Personal Promotion Submarket: Market Shares (%), 2030
Figure 4.12 Contract Tele-detailing Submarket Forecast: Revenues ($bn), 2020-2030
Figure 4.13 Contract Tele-detailing Submarket: Drivers and Restraints, 2020-2030
Figure 4.14 Contract eDetailing Submarket Forecast: Revenues ($bn),
2020-2030
Figure 4.15 Contract eDetailing Submarket Drivers and Restraints, 2020-2030
Figure 4.16 Medical Education Services Submarket Forecast: Revenues ($bn), 2020-2030
Figure 4.17 Medical Education Services Submarket: Drivers and Restraints, 2020-2030
Figure 4.18 Sample Management Services Submarket Forecast: Revenues ($bn), 2020-2030
Figure 4.19 Sample Management Services Submarket Drivers and Restraints, 2020-2030
Figure 5.1 Leading Regional Pharma Contract Sales Markets: Forecast Revenue ($bn), 2020-2030
Figure 5.2 Regional Composition of the Global Pharma Contract Sales Market: Market Shares (%), 2019
Figure 5.3 Regional Composition of the Global Pharma Contract Sales Market: Market Shares (%), 2025
Figure 5.4 Regional Composition of the Global Pharma Contract Sales Market: Market Shares (%), 2030
Figure 5.5 US Pharma Contract Sales Market Forecast: Revenue ($bn), 2020-2030
Figure 5.6 EU5 Pharma Contract Sales Market Forecast: Revenue ($bn), 2020-2030
Figure 5.7 Composition of the EU5 Pharma Contract Sales Market, 2019
Figure 5.8 Composition of the EU5 Pharma Contract Sales Market, 2030
Figure 5.9 UK Pharma Contract Sales Market Forecast: Revenue ($bn), 2020-2030
Figure 5.10 German Pharma Contract Sales Market Forecast: Revenue ($bn), 2020-2030
Figure 5.11 French Pharma Contract Sales Market Forecast: Revenue ($bn), 2020-2030
Figure 5.12 Italian Pharma Contract Sales Market Forecast: Revenue ($bn), 2020-2030
Figure 5.13 Spanish Pharma Contract Sales Market Forecast: Revenue ($bn), 2020-2030
Figure 5.14 Japanese Pharma Contract Sales Market Forecast: Revenue ($bn), 2020-2030
Figure 6.1 BRIC Pharma Contract Sales Market Forecast: Revenue ($bn), 2020-2030
Figure 6.2 BRIC Pharma Contract Sales Market Composition: Revenue ($bn), 2019
Figure 6.3 Chinese Pharma Contract Sales Market Forecast: Revenue ($bn), 2020-2030
Figure 6.4 Indian Pharma Contract Sales Market Forecast: Revenue ($bn), 2020-2030
Figure 6.5 Brazilian Pharma Contract Sales Market Forecast: Revenue ($bn), 2020-2030
Figure 6.6 Russian Pharma Contract Sales Market Forecast: Revenue ($bn), 2020-2030
Figure 7.1 Orphan Drug Pipeline by Disease Area, 2019
Figure 8.1 IQVIA Integrated Health Services Segment: Revenues ($bn), 2014-2018
Figure 8.2 UDG Healthcare: Revenues ($bn), 2015-2019
Figure 8.3 PDI: Commercial Services Revenues ($bn), 2010-2014
Figure 9.1 Pharma Contract Sales Market: Revenues ($bn) by Sector, 2019, 2025, 2030
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
